UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

~~Washington~~WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

~~Pursuant~~PURSUANT toTO ~~Section~~ SECTION 13 orOR 15(d)

ofOF ~~the~~THE ~~Securities~~SECURITIES ~~Exchange~~EXCHANGE ~~Act~~ACT ofOF 1934

Date of ~~Report~~report (Date of earliest event reported): October 2829, 2020

Livongo Health, Inc.

(Exact name of ~~registrant~~Registrant as ~~specified~~Specified in its ~~charter~~Charter)

Delaware	001-38983	~~001-38983~~	26-3542036	~~26-3542036~~
(State or other jurisdiction ofincorporation)		(Commission File Number)		(I.R.S. EmployerIdentification Number)
(State or other jurisdiction of incorporation)	(Commission File Number)		(I.R.S. Employer Identification No.)

150 West Evelyn Avenue, Suite 150

Mountain View, California 94041

(Address of ~~principal~~Principal ~~executive~~Executive ~~offices)~~Offices, (including Zip Code)

~~Registrant’s telephone number, including area code:~~ (866) 435-5643

~~Not~~(Registrant’s ~~Applicable~~telephone number, including area code)

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☒	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	~~Trading Symbol(s)~~	Name of each exchange on which registered	~~Name of each exchange on which registered~~
Common Stock, $0.001 par value		LVGO		The Nasdaq Global Select Market
Common Stock (par value $0.001 per share)	LVGO		The Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2 8.~~02.~~01 ~~Results~~Other ~~of Operations and Financial Condition~~Events.

On October 2829, 2020, Livongo Health, Inc. ~~issued~~(“Livongo”) held a ~~press~~special ~~release~~meeting ~~announcing~~of its ~~financial~~stockholders (the “Special Meeting”). At the Special Meeting, based on preliminary voting results, ~~for~~Livongo’s ~~its~~stockholders ~~third~~voted ~~quarter~~to ~~ended~~(a) adopt ~~September~~the Agreement and Plan of Merger, dated as of August 305, 2020 (the “Merger Agreement”), by and among Teladoc Health, Inc. A(“Teladoc”), ~~copy~~Livongo and Tempranillo Merger Sub, Inc., a wholly-owned subsidiary of Teladoc (the ~~press~~“Livongo ~~release~~Merger Agreement Proposal”), (b) approve, on an advisory (non-binding) basis, the executive officer compensation that will or may be paid to Livongo’s named executive officers that is ~~furnished~~based ~~herewith~~on asor ~~Exhibit~~otherwise ~~99.1~~relates ~~and~~to ~~incorporated~~the ~~herein~~transactions contemplated by ~~reference~~the Merger Agreement, and (c) approve the adjournment of the Special Meeting to solicit additional proxies if there are not sufficient votes at the time of the Special Meeting to approve the Livongo Merger Agreement Proposal or to ensure that any supplement or amendment to the joint proxy statement/prospectus is timely provided to Livongo stockholders.

~~The~~Based ~~information contained in this Current Report~~ on ~~Form 8-K and in~~ the ~~accompanying~~results ~~exhibit are “furnished” and shall not be deemed “filed” for purposes~~ of ~~Section 18 of~~ the ~~Securities~~Special ~~Exchange Act of 1934~~Meeting, subject asto ~~amended (~~the ~~“Exchange~~satisfaction ~~Act”),~~ or ~~otherwise~~waiver ~~subject~~of to the ~~liabilities~~remaining ofclosing ~~that~~conditions ~~section, and shall not be incorporated by reference in any filing~~ under the ~~Securities~~Merger ~~Act of 1933~~Agreement, asthe ~~amended,~~transactions orcontemplated by the ~~Exchange~~Merger ~~Act~~Agreement ~~regardless~~are ofexpected ~~any~~to ~~general~~be ~~incorporation~~consummated ~~language~~on ~~in such filing~~October 30, ~~unless expressly incorporated by specific reference in such filing~~2020.

~~Item 8.01.~~Cautionary ~~Other~~Note ~~Events.~~Regarding Forward-Looking Statements

This communication contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section ~~The~~27A ~~third~~of ~~paragraph~~the Securities Act of 1933, as amended, and Section 21E of the ~~fourth~~Securities ~~sentence~~Exchange Act of 1934, as amended. These forward-looking statements generally include statements regarding the ~~fourth~~potential ~~full~~transaction ~~paragraph~~between Teladoc and Livongo, including any statements regarding the expected timetable for completing the potential transaction, the ability to complete the potential transaction, the expected benefits of ~~Exhibit~~the 99potential transaction (including anticipated synergies, projected financial information and future opportunities) and any other statements regarding Teladoc’s and Livongo’s future expectations, beliefs, plans, objectives, results of operations, financial condition and cash flows, or future events or performance.1 These statements are ~~hereby~~often, ~~incorporated~~but not always, made through the use of words or phrases such as “anticipate,” “intend,” “plan,” “believe,” “project,” “estimate,” “expect,” “may,” “should,” “will” and similar expressions. All such forward-looking statements are based on current expectations of Teladoc’s and Livongo’s management and therefore involve estimates and assumptions that are subject to risks, uncertainties and other factors that could cause actual results to differ materially from the results expressed in the statements. Key factors that could cause actual results to differ materially from those projected in the forward-looking statements include the risk that a condition to closing the potential transaction may not be satisfied; the risk that the anticipated U.S. federal income tax treatment of the transaction is not obtained; litigation relating to the potential transaction that have been or could be instituted against Teladoc, Livongo or their respective directors; the effects of disruption to Teladoc’s or Livongo’s respective businesses; restrictions during the pendency of the potential transaction that may impact Teladoc’s or Livongo’s ability to pursue certain business opportunities or strategic transactions; the effect of this communication on Teladoc’s or Livongo’s stock prices; transaction costs; Teladoc’s ability to achieve the benefits from the proposed transaction; Teladoc’s ability to effectively integrate acquired operations into its own operations; the ability of Teladoc or Livongo to retain and hire key personnel; unknown liabilities; and the diversion of management time on transaction-related issues. Other important factors that could cause actual results to differ materially from those in the forward-looking statements include the effects of industry, market, economic, political or regulatory conditions outside of Teladoc’s or Livongo’s control (including public health crises, such as pandemics and epidemics); changes in laws and regulations applicable to Teladoc’s business model; changes in market conditions and receptivity to Teladoc’s services and offerings; results of litigation; the loss of one or more key clients of Teladoc (including potential adverse reactions or changes to business relationships resulting from the announcement or completion of the potential transaction); changes to Teladoc’s abilities to recruit and retain qualified providers into its network; the impact of the COVID-19 pandemic on the parties’ business and general economic conditions; risks regarding Livongo’s ability to retain clients and sell additional solutions to new and existing clients; Livongo’s ability to attract and enroll new members; the growth and success of Livongo’s partners and reseller relationships; Livongo’s ability to estimate the size of its target market; uncertainty in the healthcare regulatory environment; and the factors set forth under the heading “Risk Factors” of Teladoc’s Annual Report and Livongo’s Annual Report, in each case on Form 10-K, and in subsequent filings with the U.S. Securities and Exchange Commission (the “SEC”). These risks, as well as other risks associated with the potential transaction, are more fully discussed in the joint proxy statement/prospectus filed with the SEC in connection with the proposed transaction. Other unpredictable or unknown factors not discussed in this communication could also have material adverse effects on forward-looking statements. Neither Teladoc nor Livongo assumes any obligation to update any forward-looking statements, except as required by ~~reference~~law. Readers are cautioned not to place undue reliance on these forward-looking statements that speak only as of the date hereof.

~~Item 9.01.~~No ~~Financial~~Offer ~~Statements~~or ~~and~~Solicitation ~~Exhibits.~~

~~(d)~~This ~~Exhibits~~communication does not constitute an offer to sell or the solicitation of an offer to buy any securities or a solicitation of any vote or approval, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. No offer of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act of 1933, as amended.

Exhibit						Description
99.1						Press Release dated October 28, 2020.

Important Information for Investors and Stockholders

~~SIGNATURE~~In connection with the potential transaction, Teladoc has filed a registration statement on Form S-4 (File No. 333-248568) with the SEC containing a prospectus of Teladoc that also constitutes a definitive joint proxy statement of each of Teladoc and Livongo. The registration statement, as amended, was declared effective by the SEC on September 15, 2020. Each of Teladoc and Livongo commenced mailing copies of the definitive joint proxy statement/prospectus to stockholders of Teladoc and Livongo, respectively, on or about September 15, 2020. Teladoc and Livongo may also file other documents with the SEC regarding the potential transaction. This communication is not a substitute for the joint proxy statement/prospectus or registration statement or for any other document that Teladoc or Livongo have filed or may file with the SEC in connection with the potential transaction. INVESTORS AND SECURITY HOLDERS OF TELADOC AND LIVONGO ARE URGED TO READ THE JOINT PROXY STATEMENT/PROSPECTUS AND OTHER DOCUMENTS THAT ARE FILED OR WILL BE FILED WITH THE SEC, AS WELL AS ANY AMENDMENTS OR SUPPLEMENTS TO THESE DOCUMENTS, CAREFULLY AND IN THEIR ENTIRETY BECAUSE THEY CONTAIN IMPORTANT INFORMATION. Investors and security holders will be able to obtain free copies of the joint proxy statement/prospectus and other documents filed with the SEC by Teladoc or Livongo through the website maintained by the SEC at http://www.sec.gov. Copies of the documents filed with the SEC by Teladoc will be available free of charge on Teladoc’s website at https://ir.teladochealth.com and copies of the documents filed with the SEC by Livongo will be available free of charge on Livongo’s website at https://ir.livongo.com/. Additionally, copies may be obtained by contacting the investor relations departments of Teladoc or Livongo.

~~Pursuant~~Teladoc and Livongo and certain of their respective directors, certain of their respective executive officers and other members of management and employees may be considered participants in the solicitation of proxies with respect to the ~~requirements~~potential transaction under the rules of the ~~Securities~~SEC. ~~Exchange~~Information ~~Act~~about the directors and executive officers of ~~1934~~Teladoc is set forth in its proxy statement for its 2020 annual meeting of stockholders, which was filed with the ~~registrant~~SEC ~~has~~on ~~duly~~April 14, ~~caused~~2020. ~~this~~Information ~~report~~about tothe bedirectors ~~signed~~and executive officers of Livongo is set forth in its Annual Report on Form 10-K for the year ended December 31, 2019, which was filed with the SEC on March 24, 2020, and its ~~behalf~~proxy bystatement for its 2020 annual meeting of stockholders, which was filed with the ~~undersigned~~SEC ~~hereunto~~on ~~duly~~April 6, ~~authorized~~2020. These documents can be obtained free of charge from the sources indicated above. Additional information regarding the interests of such participants in the solicitation of proxies in respect of the potential transaction are included in the registration statement and joint proxy statement/prospectus and other relevant materials filed with the SEC.

~~Date:~~SIGNATURES ~~October 28, 2020~~

~~Livongo~~Pursuant ~~Health~~to the requirements of the Securities Exchange Act of 1934, ~~Inc.~~the ~~By:~~registrant ~~/s/~~has ~~Lee~~duly ~~Shapiro~~caused ~~Name:~~this ~~Lee~~report ~~Shapiro~~to ~~Title:~~be ~~Chief~~signed ~~Financial~~on ~~Officer~~its behalf by the undersigned hereunto duly authorized.

Date: October 29, 2020

Livongo Health, Inc.

/s/ Lee Shapiro

Lee Shapiro

Chief Financial Officer

Filing Compare · Livongo Health, Inc.